{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:10:33Z","timestamp":1790831433048,"version":"4.1.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,6,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Approximately 90% of limited-stage Hodgkin lymphoma (HL) patients are projected to be cured with standard therapy, but many do not live their expected life span because of late treatment\u2013related complications. New treatment paradigms are needed to reduce the use of radiation therapy (RT) as well as conventional chemotherapy drugs while improving upon current standard-of-care survival outcomes. In this phase 2 multicenter study, patients with non-bulky limited-stage HL received doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by brentuximab vedotin (BV) consolidation. Forty-one patients were enrolled, and patient characteristics included median age of 29 years (range, 19 to 67 years), 58% were female, 45% had unfavorable disease, and 98% had stage II disease. Based on positron emission tomography (PET)\u2013based risk stratification, patients received 2 to 6 cycles of ABVD followed by 6 cycles of BV. After ABVD followed by BV, 95% of evaluable patients (37 out of 39;\u00a095% confidence interval [CI], 83%-99%) achieved PET-negative status. In the intent-to-treat patient population, the estimated 3-year progression-free survival (PFS) rate was 92%, and the overall survival (OS) rate was 97%, with a median follow-up of 47 months. All 37 patients who achieved negative PET status after BV consolidation effectively avoided RT and remain in remission with estimated 3-year PFS and OS rates of 100%. In conclusion, BV demonstrates encouraging clinical activity when it follows ABVD therapy in limited-stage HL. Early incorporation of BV may reduce the use of RT as well as conventional chemotherapy drugs while achieving favorable survival outcomes in risk-stratified patients with non-bulky limited-stage HL. This trial was registered at www.clinicaltrials.gov as #NCT01578967.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020001871","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T15:36:01Z","timestamp":1591716961000},"page":"2548-2555","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":30,"title":["ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5674-6408","authenticated-orcid":false,"given":"Steven I.","family":"Park","sequence":"first","affiliation":[{"name":"Levine Cancer Institute, Charlotte, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Shea","sequence":"first","affiliation":[{"name":"University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oludamilola","family":"Olajide","sequence":"first","affiliation":[{"name":"University of North Carolina REX Healthcare, Raleigh, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishitha M.","family":"Reddy","sequence":"first","affiliation":[{"name":"Department of Medicine, Vanderbilt University, Nashville, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1464-5494","authenticated-orcid":false,"given":"Lihua E.","family":"Budde","sequence":"first","affiliation":[{"name":"City of Hope, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilanjan","family":"Ghosh","sequence":"first","affiliation":[{"name":"Levine Cancer Institute, Charlotte, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison M.","family":"Deal","sequence":"first","affiliation":[{"name":"Biostatistics and Data Management, University of North Carolina, Chapel Hill, NC; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne F.","family":"Noe","sequence":"first","affiliation":[{"name":"University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"first","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,6,9]]},"reference":[{"key":"2020060911360315200_B1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/mdf652","article-title":"Epidemiology and etiology of Hodgkin\u2019s lymphoma","volume":"13","author":"Thomas","year":"2002","journal-title":"Ann Oncol"},{"issue":"14","key":"2020060911360315200_B2","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1200\/JCO.2010.32.8427","article-title":"Long-term complications of lymphoma and its treatment","volume":"29","author":"Ng","year":"2011","journal-title":"J Clin Oncol"},{"issue":"17","key":"2020060911360315200_B3","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"2020060911360315200_B4","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"2020060911360315200_B5","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1016\/S2352-3026(15)00153-2","article-title":"Cardiovascular disease after treatment for Hodgkin\u2019s lymphoma: an analysis of nine collaborative EORTC-LYSA trials","volume":"2","author":"Maraldo","year":"2015","journal-title":"Lancet Haematol"},{"issue":"21","key":"2020060911360315200_B6","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2015.65.4194","article-title":"Evaluation of the risk of relapse in classical Hodgkin lymphoma at event-free survival time points and survival comparison with the general population in British Columbia","volume":"34","author":"Hapgood","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020060911360315200_B7","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Gopal","year":"2015","journal-title":"Blood"},{"issue":"9980","key":"2020060911360315200_B8","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"2020060911360315200_B9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"2020060911360315200_B10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"27","key":"2020060911360315200_B11","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020060911360315200_B12","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"2020060911360315200_B13","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ajh.25071","article-title":"Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management","volume":"93","author":"Ansell","year":"2018","journal-title":"Am J Hematol"},{"issue":"5","key":"2020060911360315200_B14","doi-asserted-by":"crossref","first-page":"608","DOI":"10.6004\/jnccn.2017.0064","article-title":"Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Hoppe","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"2020060911360315200_B15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2013-10-532184","article-title":"Risk of multiple primary malignancies following treatment of Hodgkin lymphoma","volume":"124","author":"van Eggermond","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2020060911360315200_B16","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood-2012-02-409821","article-title":"Pediatric Hodgkin lymphoma: trade-offs between short- and long-term mortality risks","volume":"120","author":"Yeh","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2020060911360315200_B17","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/annonc\/mdr013","article-title":"Reduced incidence of second solid tumors in survivors of childhood Hodgkin\u2019s lymphoma treated without radiation therapy","volume":"22","author":"Barbaro","year":"2011","journal-title":"Ann Oncol"},{"issue":"31","key":"2020060911360315200_B18","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1200\/JCO.2011.34.8268","article-title":"Second cancer risk after chemotherapy for Hodgkin\u2019s lymphoma: a collaborative British cohort study","volume":"29","author":"Swerdlow","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020060911360315200_B19","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2000.18.3.498","article-title":"Risk of second malignancy after Hodgkin\u2019s disease in a collaborative British cohort: the relation to age at treatment","volume":"18","author":"Swerdlow","year":"2000","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020060911360315200_B20","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/bjh.16232","article-title":"No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy","volume":"188","author":"Lagerl\u00f6f","year":"2020","journal-title":"Br J Haematol"},{"issue":"4","key":"2020060911360315200_B21","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2020060911360315200_B22","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"issue":"16","key":"2020060911360315200_B23","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","article-title":"Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines","volume":"129","author":"van Nimwegen","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2020060911360315200_B24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/sj.bmt.1704124","article-title":"Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma","volume":"32","author":"Howe","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2020060911360315200_B25","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/bjc.2012.228","article-title":"Long-term survival after treatment for Hodgkin\u2019s disease (1973-2002): improved survival with successive 10-year cohorts","volume":"107","author":"Bessell","year":"2012","journal-title":"Br J Cancer"},{"issue":"23","key":"2020060911360315200_B26","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1182\/blood-2014-05-579193","article-title":"Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects","volume":"124","author":"Ng","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2020060911360315200_B27","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","article-title":"CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET","volume":"132","author":"Straus","year":"2018","journal-title":"Blood"},{"issue":"16","key":"2020060911360315200_B28","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"issue":"31","key":"2020060911360315200_B29","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: Final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"issue":"11","key":"2020060911360315200_B30","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2016-03-703470","article-title":"Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma","volume":"128","author":"Kumar","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2020060911360315200_B31","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood.2019001272","article-title":"Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood"},{"issue":"13","key":"2020060911360315200_B32","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin\u2019s lymphoma: a phase 1, open-label, dose-escalation study","volume":"14","author":"Younes","year":"2013","journal-title":"Lancet Oncol"},{"issue":"10","key":"2020060911360315200_B33","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood.2019003127","article-title":"Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","volume":"135","author":"Straus","year":"2020","journal-title":"Blood"},{"key":"2020060911360315200_B34","first-page":"36","article-title":"Treatment strategies to optimize outcomes with brentuximab vedotin: Management of common and rare toxicities","volume":"4","author":"Fanale","year":"2015","journal-title":"J Target Ther Cancer"},{"issue":"18","key":"2020060911360315200_B35","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2014-03-561878","article-title":"Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event","volume":"123","author":"Gandhi","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2020060911360315200_B36","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjh.15255","article-title":"Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes","volume":"182","author":"Parsons","year":"2018","journal-title":"Br J Haematol"},{"issue":"10","key":"2020060911360315200_B37","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3324\/haematol.2016.141846","article-title":"Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes","volume":"101","author":"Kumar","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"2020060911360315200_B38","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/bloodadvances.2019001023","article-title":"Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I\/IIA Hodgkin lymphoma","volume":"4","author":"Illidge","year":"2020","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/11\/2548\/1744182\/advancesadv2020001871.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/11\/2548\/1744182\/advancesadv2020001871.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T15:36:27Z","timestamp":1591716987000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/11\/2548\/460730\/ABVD-followed-by-BV-consolidation-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,9]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,6,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020001871","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,9]]}}}